BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif., May  05, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 1, 2020, the compensation committee of BridgeBio’s board of directors granted five employees options to purchase an aggregate of 39,600 shares of the Company’s common stock with a per share exercise price of $28.97 and restricted stock units for an aggregate of 18,230 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

BridgeBio Pharma Reports - Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Corona Anchor Series: BridgeBio Is A Secure Long-Term Investment

BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why BridgeBio (BBIO) Stock Might be a Great Pick

PALO ALTO, Calif., April  03, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the compensation committee of BridgeBio’s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company’s common stock with a per share exercise price of $25.08 and restricted stock units for an aggregate of 22,993 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

BridgeBio Pharma Reports  Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

PALO ALTO, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering of $350 million aggregate principal amount of notes. In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes.

BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

PALO ALTO, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $52.5 million aggregate principal amount of notes.

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

PALO ALTO, Calif., March  03, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 2, 2020, the compensation committee of BridgeBio’s board of directors granted two new employees options to purchase an aggregate of 5,812 shares of the Company’s common stock with a per share exercise price of $32.21 and restricted stock units for an aggregate of 2,484 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

BridgeBio Pharma  Reports  Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia

BridgeBio Pharma, Inc. Appoints Ronald J.

PALO ALTO, Calif., Feb.  05, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 3, 2020, the compensation committee of BridgeBio’s board of directors granted nine new employees options to purchase an aggregate of 96,361 shares of the Company’s common stock with a per share exercise price of $34.81 and restricted stock units for an aggregate of 23,647 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

BridgeBio Pharma  Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

-New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder -New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

Catalent

PALO ALTO, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center in Harmans, Maryland. The agreement is intended to support the clinical and commercial manufacturing needs for BridgeBio’s gene therapy product candidates for congenital adrenal hyperplasia, BBP-631, and Canavan disease, BBP-812.

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

BOSTON, Dec.  18, 2019  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin (BBP-870/ORGN001) in Israel.

BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

Genentech veteran brings global commercial expertise to Board of Directors and will serve as a Special Advisor Genentech veteran brings global commercial expertise to Board of Directors and will serve as a Special Advisor

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

BridgeBio Pharma (NASDAQ: BBIO) is a U.S.-based early stage bio-pharmaceutical development company relying on gene sequencing.

Why BridgeBio Pharma Is Currently Trading At 2x Its IPO Price

Dr. Wallace brings over two decades of experience in oncology drug discovery to leadership team Dr. Wallace brings over two decades of experience in oncology drug discovery to leadership team

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

PALO ALTO, Calif., Dec.  05, 2019  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the compensation committee of BridgeBio’s board of directors granted eight new employees options to purchase an aggregate of 62,745 shares of the Company’s common stock with a per share exercise price of $31.14 and restricted stock units for an aggregate of 23,980 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

BridgeBio Pharma (BBIO) Reports  Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec.  03, 2019  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

Eidos Therapeutics Inc

BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?

BridgeBio Calls Off Its Acquisition Offer for Eidos Therapeutics

Axsome Therapeutics

Kodiak Sciences Inc

These small-cap biotechs have fallen to bargain prices.

3 Top Biotech Stocks to Buy in October

Preclinical study designed to test investigational agent infigratinib for the treatment of glioblastoma Preclinical study designed to test investigational agent infigratinib for the treatment of glioblastoma

Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

Provides BridgeBio with leading scientific expertise to develop oral small molecule therapy for LGMD2i Provides BridgeBio with leading scientific expertise to develop oral small molecule therapy for LGMD2i

BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2 (LGMD2i) with new subsidiary ML Bio Solutions

Shares are up 75% from IPO pricing at $17 per share, but have finished flat from levels they opened at on the open market.

News for BridgeBio Pharma Inc Stock (BBIO)